1. Home
  2. IHG vs BIIB Comparison

IHG vs BIIB Comparison

Compare IHG & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IHG
  • BIIB
  • Stock Information
  • Founded
  • IHG 1777
  • BIIB 1978
  • Country
  • IHG United Kingdom
  • BIIB United States
  • Employees
  • IHG N/A
  • BIIB N/A
  • Industry
  • IHG Hotels/Resorts
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • IHG Consumer Discretionary
  • BIIB Health Care
  • Exchange
  • IHG Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • IHG 17.0B
  • BIIB 18.7B
  • IPO Year
  • IHG N/A
  • BIIB 1991
  • Fundamental
  • Price
  • IHG $130.26
  • BIIB $165.12
  • Analyst Decision
  • IHG Hold
  • BIIB Buy
  • Analyst Count
  • IHG 3
  • BIIB 24
  • Target Price
  • IHG N/A
  • BIIB $174.62
  • AVG Volume (30 Days)
  • IHG 171.1K
  • BIIB 1.6M
  • Earning Date
  • IHG 01-01-0001
  • BIIB 10-30-2025
  • Dividend Yield
  • IHG 1.27%
  • BIIB N/A
  • EPS Growth
  • IHG 21.99
  • BIIB N/A
  • EPS
  • IHG 4.70
  • BIIB 10.97
  • Revenue
  • IHG $5,120,000,000.00
  • BIIB $10,065,900,000.00
  • Revenue This Year
  • IHG N/A
  • BIIB $2.97
  • Revenue Next Year
  • IHG $6.21
  • BIIB N/A
  • P/E Ratio
  • IHG $26.34
  • BIIB $14.72
  • Revenue Growth
  • IHG 33.89
  • BIIB 4.77
  • 52 Week Low
  • IHG $94.78
  • BIIB $110.04
  • 52 Week High
  • IHG $137.25
  • BIIB $175.86
  • Technical
  • Relative Strength Index (RSI)
  • IHG 62.99
  • BIIB 72.29
  • Support Level
  • IHG $131.15
  • BIIB $151.83
  • Resistance Level
  • IHG $132.57
  • BIIB $157.79
  • Average True Range (ATR)
  • IHG 2.02
  • BIIB 5.37
  • MACD
  • IHG 0.84
  • BIIB 1.14
  • Stochastic Oscillator
  • IHG 81.70
  • BIIB 90.11

About IHG Intercontinental Hotels Group

InterContinental Hotels Group operates 987,000 rooms across 19 brands addressing the midscale through luxury segments, as of Dec. 31, 2024. Holiday Inn and Holiday Inn Express constitute the largest brand, while Hotel Indigo, Even, Hualuxe, Kimpton, and Voco are newer lifestyle brands experiencing strong demand. The company launched a midscale brand, Avid, in 2017 and closed on a 51% stake in Regent Hotels in 2018. It acquired Six Senses in 2019 and launched another midscale brand, Garner, in 2023. Managed and franchised represent 99% of total rooms. As of Dec. 31, 2024, the Americas represented 53% of total rooms, with Greater China accounting for 20% and Europe, Asia, the Middle East, and Africa making up 27%.

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Share on Social Networks: